Hospital
State of West Virginia Welch Community Hospital
State of West Virginia Welch Community Hospital was paid $4.56M by Medicaid between Jan 2018 and Dec 2024, across 115 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoSTATE OF WEST VIRGINIA WELCH COMMUNITY HOSPITAL
WELCH, WV 24801
WELCH, WV 24801
33aNPI1134158900assigned 07/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.56M
24GClaims243,102
24DCodes billed115
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#19 of 26
Median peer was paid$18.33M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,212 | $676K | |
| 2019 | 25,065 | $489K | |
| 2020 | 44,455 | $1.07M | |
| 2021 | 39,218 | $751K | |
| 2022 | 33,082 | $549K | |
| 2023 | 37,613 | $548K | |
| 2024incomplete | 30,457 | $479K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 9,131 | 7,748 | $1.11M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 2,439 | 1,985 | $686K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 4,921 | 4,402 | $331K |
| 80053 | Comprehensive metabolic panel | 3.5% | 16,271 | 13,160 | $160K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.1% | 18,985 | 15,148 | $141K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.0% | 9,548 | 6,456 | $137K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 2,123 | 1,948 | $122K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 836 | 707 | $106K |
| 36415 | Collection of venous blood by venipuncture | 2.2% | 16,228 | 12,936 | $100K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 2,031 | 1,678 | $81K |
| 81001 | 1.7% | 15,829 | 13,254 | $78K | |
| 80050 | General health panel | 1.7% | 2,321 | 2,039 | $77K |
103 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 5,727 | $66K |
| G0378 | Hospital observation service, per hour | 1.2% | 629 | $56K |
| 74022 | 1.2% | 3,013 | $55K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 4,344 | $54K |
| 80305 | 1.2% | 3,912 | $54K | |
| 84484 | 1.1% | 5,903 | $52K | |
| 82805 | 1.1% | 1,301 | $52K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 5,224 | $46K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 1,720 | $46K |
| 87430 | <1% | 3,566 | $45K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,821 | $42K |
| 83690 | <1% | 5,229 | $41K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,052 | $41K |
| 82150 | <1% | 5,084 | $39K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 628 | $35K |
| 87088 | <1% | 6,984 | $33K | |
| 86318 | <1% | 1,738 | $30K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 79 | $28K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 74 | $28K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 704 | $28K |
| 85730 | <1% | 4,122 | $25K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,064 | $25K |
| 84703 | <1% | 2,298 | $25K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,695 | $24K |
| 99001 | <1% | 1,301 | $24K | |
| 86140 | <1% | 5,144 | $23K | |
| 85610 | <1% | 4,571 | $23K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,262 | $21K |
| 87040 | <1% | 1,156 | $20K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,806 | $20K |
| 83880 | <1% | 1,503 | $20K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 311 | $20K |
| 80061 | Lipid panel | <1% | 1,568 | $19K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,990 | $18K |
| 83735 | <1% | 4,138 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,800 | $15K |
| 84436 | <1% | 1,493 | $15K | |
| 85379 | <1% | 1,211 | $14K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,532 | $14K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,505 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 682 | $12K |
| 87070 | <1% | 1,038 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 95 | $11K |
| 84479 | <1% | 1,136 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,421 | $10K |
| 72110 | <1% | 406 | $9K | |
| 86403 | <1% | 546 | $7K | |
| 73130 | <1% | 241 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,723 | $6K |
| 73630 | <1% | 269 | $5K | |
| 83605 | <1% | 544 | $5K | |
| 80320 | <1% | 519 | $5K | |
| 73562 | <1% | 262 | $5K | |
| 94760 | <1% | 54 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 287 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 67 | $4K |
| 73610 | <1% | 239 | $3K | |
| 83518 | <1% | 339 | $3K | |
| 96376 | <1% | 227 | $3K | |
| 84702 | <1% | 213 | $3K | |
| 73030 | <1% | 180 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 77 | $3K |
| 87075 | <1% | 196 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 119 | $2K |
| 74246 | <1% | 17 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 613 | $2K |
| 84100 | <1% | 109 | $2K | |
| 82553 | <1% | 28 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 105 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 120 | $1K |
| 82140 | <1% | 93 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $1K |
| 73110 | <1% | 96 | $1K | |
| 94664 | <1% | 248 | $971.81 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 27 | $895.87 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 39 | $840.00 |
| 80329 | <1% | 243 | $833.92 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 383 | $707.25 |
| 82550 | <1% | 35 | $658.36 | |
| 86703 | <1% | 55 | $643.43 | |
| 73564 | <1% | 27 | $590.80 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 325 | $521.00 |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $509.40 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,929 | $498.70 |
| 80074 | <1% | 13 | $471.57 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,130 | $438.59 |
| 82607 | <1% | 43 | $399.16 | |
| 82728 | <1% | 36 | $360.33 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 67 | $259.88 |
| 73590 | <1% | 15 | $224.54 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 262 | $202.70 |
| 86803 | <1% | 16 | $192.60 | |
| 86900 | <1% | 54 | $188.94 | |
| 86886 | <1% | 16 | $163.89 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 19 | $145.66 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 35 | $106.86 |
| 74018 | <1% | 14 | $100.24 | |
| 84550 | <1% | 16 | $87.08 | |
| 86592 | <1% | 15 | $53.76 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $44.85 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 28 | $40.42 |
| 86901 | <1% | 13 | $24.21 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 32 | $1.26 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIMPSON, MARK (CEO)
| Provider | Location | Paid |
|---|---|---|
| State of West Virginia Welch Community Hospital | Welch, WV | $4.19M |
| Mark Simpson, PC | Hixson, TN | $19K |
| Mark Simpson PSYD Mac Ladc LLC | Albuquerque, NM | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.